REG - AstraZeneca PLC - AstraZeneca plans new R&D centre in Massachusetts

AstraZenecaAnnouncement

29/04/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220429:nRSc7892Ja&default-theme=true

RNS Number : 7892J  AstraZeneca PLC  29 April 2022

29 April 2022 07:05 BST

 

AstraZeneca announces plans for new strategic R&D centre and Alexion
headquarters in Cambridge, Massachusetts

Move brings together AstraZeneca and Alexion colleagues in a purpose-built
facility in Kendall Square, Cambridge, MA, a world leading life sciences hub

AstraZeneca today announced plans to open a new site at the heart of the
Cambridge, MA, life sciences and innovation hub.

 

The new site will be a strategic R&D centre for AstraZeneca, as well as
Alexion's new corporate headquarters. The site will bring together
approximately 1,500 R&D, commercial and corporate colleagues into a single
purpose-built space in Kendall Square, Cambridge, MA.

 

The site, scheduled for completion in 2026, will be in close proximity to
several major academic, pharma and biotech institutions, inspiring greater
collaboration and innovation potential, and providing access to future talent.
The move reinforces AstraZeneca's commitment to the greater Boston area, with
over 570,000 square feet of R&D and commercial space, and room for
expansion for the future.

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's
announcement is a milestone moment following the acquisition of Alexion in
July 2021. Our combined company has already successfully leveraged internal
scientific synergies, and this move will act as a catalyst for even more
external collaboration and innovation.

 

"Kendall Square, Cambridge, is at the heart of the life sciences and
innovation hub of the greater Boston area, and our new site will put us right
at the centre of this space. The move will provide access to some of the most
innovative partners in academia and biotech, offering opportunities to
accelerate our growth and collaborate with like-minded organisations as we
continue to push the boundaries of science to deliver advances for patients."

 

Notes

AstraZeneca is working with BXP (NYSE:BXP) on development of the new site.

 

In line with AstraZeneca's commitment to leading in sustainability, the aim is
for the new site to have platinum Leadership in Energy & Environmental
Design (LEED) certification, the highest level of certification.

 

Alexion's R&D center of excellence will remain in New Haven, Connecticut.
Alexion recently signed a lease to expand that campus as well, which will
double Alexion's lab floor space in New Haven by the end of 2023.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

Contacts
For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFSLSVITFIF